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Abstract. Previous phase I DNA‑vaccine based clinical trials
using Mammaglobin‑A (Mam‑A), a human breast tumor
associated antigen (TAA), demonstrated that this agent was
safe and efficient at treating patients with stage IV breast
cancer. The long‑term success of cancer vaccines is limited
by the diminished expression of human leukocyte antigen
(HLA) class I molecules in the tumor microenvironment. The
current study assessed the impact of various selenocompounds
on the expression of HLA class I molecules in THP‑1 cells,
an apparent proficient antigen that presents a human monocyte‑like cell line, and their eventual activation of MamA2.1
(HLA‑A2 immunodominant epitope of Mam‑A) specific cytotoxic CD8+ T lymphocytes (CTLs). The results revealed that,
following treatment with methylselenol producing compounds
[methylselenic acid (MSA) and dimethylselenide (DMDSe)],
the expression of HLA class‑I was increased and components
involved with the antigen presentation machinery of THP‑1
cells were upregulated. Furthermore, CTLs activated by
MamA2.1 peptide presenting THP‑1 cells, pre‑treated with
MSA and DMDSe, demonstrated an enhanced cytotoxicity
in HLA‑A2+/Mam‑A+ AU565 and UACC‑812 breast cancer
cell lines when compared with CTLs activated by THP‑1 cells
without drug treatment. However, no significant cytotoxicity
was observed under similar conditions in HLA‑A2+/Mam‑A‑
MCF‑7 and MDA‑MB‑231 breast cancer cell lines. The
results indicated that treatment with methylselenol producing
compounds retained antigen‑dependent activation of CD8+
T cells. The data of the current study demonstrated that MSA
and DMDSe potentiated effector cytotoxic responses following
TAA specific activation of CTLs, indicating their future role
as vaccine adjuvants in cancer immunotherapy.
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Introduction
Tumors adopt various immune escape strategies to avoid
recognition and elimination by cytotoxic CD8+ T lymphocytes (CTLs) (1). A major mechanism by which tumors
escape immune recognition is by downregulating their
surface expression of human leukocyte antigen (HLA)
class I molecules. A major explanation for the disappointing
outcome from DNA and peptide‑based anti‑cancer vaccines
is that the minimal tumoral expression of HLA class I
molecules do not allow for the vaccine activated CTLs to
exert their cancer eliminating cytotoxic effect in the tumor
microenvironment (2). Similarly, decreased HLA expression
is also considered to play a deleterious role in the favorable
clinical outcomes of immune checkpoint inhibitor based
cancer immunotherapeutic strategies. A decreased HLA
class I expression is noted in various solid organ tumors
including breast cancers (3). Hence, there is an important
need to develop novel approaches to enhance HLA class I
expression to overcome tumor immune escape and promote
tumor rejection. Further, potential HLA class I recovery in
the tumor microenvironment will complement the clinical
outcome of various anti‑tumor immunotherapeutic strategies
including vaccine based approaches.
Active metabolite derivatives of Selenium (Se) have been
suggested to exert an anti‑carcinogenic effect on many solid
organ tumors such as prostate and breast cancer (4). Clinical
interventional studies demonstrated that a supra‑nutritive
intake of Se has positive effects in the prevention of several
solid organ cancers (5). The two key metabolites of Se (Fig. 1A),
hydrogen selenide (H2Se), derived mainly from inorganic selenocompounds such as selenate or selenite, and methylselenol
(CH3SeH), derived from organic selenocompounds, such as
methyl selenic acid (MSA) and dimethylselenide (DMDSe),
have been shown to be crucial for the biological function of
these selenocompounds (6,7). While the exact mechanisms
of action of this anti‑carcinogenic effect of selenium derivatives are unknown, several studies have suggested that the
Se metabolite, methylselenol, is the active Se compound for
anti‑carcinogenic effects while remaining non‑cytotoxic on
normal terminally differentiated cells. Murine tumor studies
have shown that combined treatment of MSA with paclitaxel
reduced tumor growth of tumor xenografts with triple negative
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breast cancer cells (TNBC) compared to paclitaxel treatment
alone (8).
Mammaglobin‑A (Mam‑A) is a human breast tumor‑associated antigen (TAA) expressed in 40‑80% of primary and
metastatic breast cancers (9‑13). Previously, we have demonstrated that Mam‑A based vaccination to stage‑IV human breast
cancer patients was safe and efficient in increasing progression
free survival in vaccinated patients. Murine and in vitro studies
have demonstrated that HLA‑A2‑restricted MamA2.1 peptide
(amino acids 83‑92 of Mam‑A, LIYDSSLCDL) exerted specific
immunodominance towards effector cytotoxic activation
of naïve CD8+ T lymphocytes (14,15). While we have shown
that following Mam‑A vaccination there was some increase in
the frequency of MamA2.1+CD8 T cells, strategies to further
enhance HLA class I expression will provide an additional
adjuvant methodology to enhance vaccine efficiency. Therefore,
in this communication, we studied the role of selenium
compounds towards increasing the cytotoxic efficiency of
HLA‑A2 restricted Mam‑A epitope (MamA2.1) activated CTLs
on Mam‑A expressing human breast cancer cells.

and injected into the HPLC system. The Agilent 1100 HPLC
system was comprised of isocratic pump (G1310A) and an auto
sampler (G1313A). The Gemini C18 (3 µM, 110 Å, 50x1 mm
inner diameter) columns were utilized for chromatography.
The mobile phase was 0.1% formaldehyde in 40% methanol.
The flow rate was 100 µl/min. Injection volumes were 10 µl.
Data were analyzed with Chemstation software.

Materials and methods

Flow cytometry. The HLA‑A2 expression in cells were
analyzed by flow cytometry using appropriated primary
(BB7.2, BioLegend, San Diego, CA, USA) and FITC‑labelled
secondary antibody. Samples were analyzed using a FACS
Calibur/LSRII flow cytometer (BD Biosciences, Franklin
Lakes, NJ, USA). Data were analyzed using BD FACSDiva
software. Gates were set according to isotype controls.

Cell lines and healthy human CD8+ T lymphocytes. The
human breast cancer cell lines were selected based on the
specific expression of antigen presenting class I HLA‑A2
molecule and expression of tumor specific antigen, mammaglobin‑A. The following cell lines: MAM-A+/HLA‑A2+
(AU565 and UACC‑812) and MAM-A-/HLA‑A2+ (MCF‑7 and
MDA‑MB‑231), and human monocyte‑like HLA‑A2+ cell line,
THP‑1 cells, were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Human CD8+ T cells
from HLA‑A2+ healthy subjects were obtained from StemCell
Technologies (Cambridge, MA, USA). All cell cultures and
incubations were performed as per provider's recommendations and described by us before (16). Briefly, cell were cultured
in RPMI‑1640 medium at 37˚C in 5% CO2 incubator until they
were 80% confluent. The presence of Mam‑A and HLA‑A2
expression in the breast cancer cell lines was confirmed by
western blot analysis (data not shown). The selenocompounds,
methylseleninic acid (MSA), dimethylselenide (DMDSe) and
selenomethionine (SeMet) were obtained from Sigma-Aldrich;
Merck KGaA, Darmstadt, Germany. The THP‑1 cells were
cultured in 24 well plates, 1x105 per well and stimulated with
respective selenocompounds (5 µM) for 24 h. These cells were
later used for various experiments detailed below. For MamA2.1
peptide stimulation (Peptide 2.0 Inc, Chantilly, VA), CD8+ T
lymphocytes (1x106) were cultured in 2 ml of supplemented
RPMI‑1640 media in 24‑well plates in the presence of irradiated (5,000 rads) THP‑1 cells (1x106) loaded with Mam‑A2.1 in
the presence of β2 m (3 µg/ml), CD3 (500 ng/ml), CD28 mAb
(500 ng/ml) and recombinant human IL‑2 (20 U/ml). The CD8+
T lymphocytes were isolated by immunomagnetic separation
(MACS Miltenyi Biotec, San Diego, CA) and the resulting
purity was verified to be >95%. The MamA2.1 peptide was
custom synthesized by Peptide 2.0 Inc. (Chantilly, VA) and
purified on HPLC column to >95% purity.
High‑performance liquid chromatography. The supernatant from
cell cultures were treated with methanol (1:1 final concentration)

Cytotoxicity assay. The cytotoxic efficiency of peptide‑activated
CD8+ T cells was investigated by its ability to lyse the target
breast cancer cells by non‑irradiative LDH release assay
(Promega Corporation, Madison, WI, USA) and and MTT assay
(Life Technologies; Thermo Fisher Scientific, Inc., Waltham,
MA, USA). The breast cancer cells (1x104 cells) in 100 µl of
complete medium at were plated in triplicate cultures in round
bottom 96‑well plates in the presence of varying numbers
of CD8+ T cells (6.25:1 to 50:1) and incubated at 37˚C. The
percentage specific lysis was calculated as follows: [(experimental LDH release‑spontaneous LDH release)/(maximum
LDH release‑spontaneous LDH release)] x100.

ELISA. The secretory extracellular IFNγ in the cell supernatant
was quantitated by ELISA as per the manufacturer's protocol
(R&D Systems, Minneapolis, MN, USA; catalog# DY285B).
Quantification was performed with a standard curve using
the manufacturer provided standards. Detection at 450 nm
was performed using EMax Plus spectrophotometer and data
analysis was carried out using software provided by the manufacturer (Molecular Devices, Sunyvale, CA, USA).
Western blotting. Total proteins were extracted from cells with
lysis buffer for western blot analysis as previously described.
Total proteins were separated on a 4‑12% sodium dodecyl
sulfate‑polyacrylamide gradient gel and transferred onto a
nitrocellulose membrane. All primary and secondary Abs
were obtained from Abcam (Cambridge, MA, USA) or Santa
Cruz Biotechnology, Inc. (Dallas, TX, USA). The following
specific primary antibodies to TAP‑1 (sc‑376796, Santa
Cruz Biotechnology, Inc., 1:200), TAP‑2 (sc‑515576, Santa
Cruz Biotechnology, Inc., 1:200), LMP‑2 (ab3328, Abcam,
1:500), LMP‑7 (ab3329, Abcam, 1:500), tapasin (ab196764,
Abcam, 1:500), β2‑microglobulin (sc‑515576, Santa Cruz
Biotechnology, Inc., 1:200) and β‑actin (sc‑8432, Santa Cruz
Biotechnology, Inc., 1:200). The following specific secondary
antibodies were used based the species of the primary antibody: goat anti‑mouse‑HRP (ab205718, Abcam, 1:2,500) and
goat anti‑rabbit‑HRP (ab205718, Abcam, 1:2,500). The transferred and probed nitrocellulose membranes were developed
using the chemiluminescence kit (EMD Millipore, Billerica,
MA, USA) and analyzed on using Bio‑Rad Universal Hood II
(Hercules, CA, USA). Morphometric analysis was done using
the software provided by the company.
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Table I. Primer sequences used for reverse transcription‑quantitative PCR.
				Product
Gene
Forward (5'‑3')
Reverse (5'‑3')
Acc. no.
lenght (bp)
Tap1
Tap2
LMP2
LMP7
Tapasin
B2m
Jak1
Jak2
Stat1
Stat2
Stat3
Irf1
Irf2
Irf5
Irf7
Irf9
GAPDH
β‑actin

TGCCTAAGAAGCTGGGAAAA
CGGTGCTAAAGGAGATCCAG
TCTTCTGTGCCCTCTCAGGT
GGAACGCATCTCCGTGTCTG
ACACTGCGAGATGAGCCGCTTC
GCCGAACATACTGAACTGCT
CCGCATGAGGTTCTACTTTACC
GCAGATTCATTCAGCAATTCAG
GACACCTGCAACTGAAG
CTGAAGGAGATGAGTCACATGC
ACAACGCTGGCTGAGAAGCTCC
GAAGATAGCCGAAGACCT
GGTCCTGACTTCAGCTAT
GTCAAGACGAAGCTCTTTAGCC
GTTTACGAGGAACCCTATGCAG
GCGTTGTAAACCACTCAGACAG
TTGTGCAGTGCCAGCCTCGT
ACTGTCGAGTCGCGTCC

GTAAGCCAAGGCCTCCTTCT
CCATCACCCTCCGTATGACT
TGGTCCCAGCCAGCTACTAT
CTGCCGGTAACCACTGTCCA
TGAGGACGGTCAGCACCACTGT
GCCATACTGGCATGCTTAAC
TCAAATCATACTGTCCCTGTGC
CGTCCTGTTCTGTCAGTGTCTC
CACCAGCATGTTGTACC
GGTGAACTTGTTCCCAGTCTTC
TTGTGCTTAGGATGGCCCGCTC
CTTCATCTCCGTGAAGAC
TTCTGCGTAGGAAGACAG
CTGCTCTACCATGTGGTCTTTG
GAAGCGTCTCTGTGTAGTGCAG
CATAGATGAAGGTGAGCAGCAG
TCGGCCTTGACTGTGCCGTT
ATGGCTACGTACATGGCTGG

Reverse transcription‑quantitative PCR (RT‑qPCR). Expression
profiles of genes at mRNA level in the breast cancer cell lines
were analyzed using the SyBr‑green detection based RT‑qPCR
primers (Table I), obtained from Integrated DNA Technologies
(San Jose, CA, USA). Briefly, total RNA was extracted from
106 cells using TRIzol reagent (Sigma-Aldrich; Merck KGaA)
and analyzed as mentioned previously. The cycling conditions
consisted of an initial denaturation of 95˚C for 15 min, followed
by 40 cycles of 95˚C for 30 sec, followed by 61˚C for 1 min. The
final reaction volume of 50 µl using BioRad CFX96 (Hercules)
and analyzed by 2‑ΔΔCq method (17).
Statistical analysis. Data are expressed as mean ± SEM from
four independent studies. Significant differences between
groups were assessed using Tukey HSD pair‑wise comparisons
for two groups and one‑way ANOVA for multiple comparisons. A p‑value of <0.05 was considered significant.
Results
Enhanced HLA class I expression following treatment with
methylselenol producing selenocompounds. As upregulation of HLA class I molecules in the tumor‑infiltrating
immune cells is considered critical for cancer immunotherapy, we first examined the potential impact of the three
selenocompounds, namely methylseleninic acid (MSA),
dimethyldiselenide (DMDSe) and selenomethionine (SeMet),
towards modulation of the surface expression of HLA class I
molecules on THP‑1 cells. As the metabolite methylselenol
is volatile, we investigated the production of dimethylselenol
(DMSe; Fig. 1A) following treatment with various selenium
compounds (18,19). We first tested for DMSe production by

NM_013683.2
NM_011530.3
NM_013585.2
NM_010724.2
NM_009318.2
NM_009735.3
NM_146145.2
NM_008413.3
NM_001205313.1
NM_019963.1
NM_213659.3
NM_001159396.1
NM_008391.4
NM_001252382.1
NM_001252601.1
NM_001159417.1
NM_008084.3
NM_007393.5

203
204
193
223
221
207
179
240
239
189
226
205
220
279
277
204
214
487

THP‑1 cells following treatment with selenocompounds for
72 h. As shown in Fig. 1B, there was an enhanced DMSe
production following treatment with MSA and DMDSe, while
there was no production of DMSe following treatment with
SeMet. We next tested the cell surface expression of HLA‑A2
on THP‑1 cells following treatment with selenocompounds.
As shown in Fig. 1C‑F, DMDSe (2.5 µM) induced a 2.4-fold
increased expression of HLA‑A2 (from 29.8±4.3%, without
treatment, to 71.7±9.1% following DMDSe treatment, P<0.05)
on THP‑1 cells. Further, MSA (2.5 µM) induced a 2.3-fold
increased expression of HLA‑A2 molecules, while SeMet
(1‑50 µM) did not induce any change in HLA‑A2 expression
on THP‑1 cells. These data suggest that MSA and DMDSe
induced enhanced expression of HLA class I molecules which
could have a critical adjuvant role in antigen presentation,
eventually leading to potential immune mediated elimination
of tumor cells following anti‑tumor vaccination.
Upregulation of antigen presenting machinery following
treatment with methyl selenol producing selenocompounds.
To determine the molecular mechanisms leading to the
enhanced upregulation of the HLA‑A2 surface expression
following treatment with selenocompounds, we analyzed the
changes in the expression of molecules involved in the surface
expression of HLA class I molecules, also known as antigen
presentation machinery (APM). As shown in Fig. 2, treatment
with MSA and DMDSe increased the protein and mRNA transcript levels of key APM components, namely, TAP‑1, TAP‑2,
LMP‑2, LMP‑7, tapasin and β2‑microglobulin in THP‑1 cells.
However, SeMet treatment did not induce the expression of
the APM components. These data demonstrate that the MSA
and DMDSe induced the APM which has a potential to induce
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Figure 1. HLA‑A2 expression in THP‑1 cells following treatment with selenocompounds. (A) Schematic of selenocompound metabolism. (B) Production of
DMSe by THP‑1 cells following treatment with SeMet (50 µM), MSA (2.5 µM) and DMDSe (2.5 µM). DMSe could be further methylated to unstable TMSe.
Pure DMSe at 1 µM in cell culture media was analyzed and used as positive control. (C) HLA‑A2 surface expression on THP‑1 cells following treatment with
SeMet (50 µM), MSA (2.5 µM) or DMDSe (2.5 µM). Percent expression was analyzed via isotype labelled negative control antibody staining. (D‑F) Dose
response following treatment (D) SeMet, (E) MSA and (F) DMDSe to assess the expression of HLA‑A2. Data are presented as the mean ± SEM (n=4).
Statistical significance for C, D and E were analyzed via one‑way ANOVA. *P<0.05 vs. 0 µM. HLA, human leukocyte antigen; SeMet, selenomethionine; MSA,
methylselenic acid; DMDSe, methylselenol derivative dimethyl selenol; TMSe, trimethy selenol; MFI, mean fluorescence intensity.

tumor associated antigen specific effector CD8+ T cell immune
responses against cancer cells.
Enhanced activation of Mam‑A specific effector CD8+
T lymphocyte mediated cytotoxic responses following treat‑
ment with selenocompounds. As our data demonstrated that
following MSA and DMDSe treatment there was enhanced
HLA‑A2 expression on THP‑1 cells, we next determined
if this enhanced expression enabled HLA class‑I immunodominant MamA2.1 peptide presentation and eventual
antigen‑specific CD8+ T cell activation leading to cell mediated cytotoxicity against breast cancer cells. We therefore
stimulated naïve CD8+ T lymphocytes collected from healthy
HLA‑A2+ human subjects with MamA2.1peptide in the presence of antigen presenting HLA‑A2+ THP‑1 mononuclear cells
pre‑treated with selenocompounds (Fig. 3A). We collected
these activated CD8+ T cells by magnetic beads isolation
and ascertained the purity (>95%) by flow cytometry. We
investigated if these MamA2.1 activated CD8+ T cells exerted
higher cytotoxicity against breast cancer cell lines compared
to activation by THP‑1 cells without selenocompound treatment. The breast cancer cell lines (referred to as target cells)
and MamA2.1 activated CD8+ T cells (referred to as effector
cells) were co‑cultured. The cytotoxic effect was analyzed
by LDH release assay and measured at various effector to

target (E:T) ratios (6.25: 1 to 50:1). As shown in Fig. 3B‑E, the
MamA2.1‑specific CD8+ T lymphocytes exerted higher cytotoxicity on HLA‑A2+/MamA+ AU565 and UACC‑812 breast
cancer cell lines. The CD8+ T cells activated by THP‑1 cells
pre‑treated with MSA (72±8%, P<0.05) and DMDSe (66±11%,
P<0.05) exerted higher cytotoxicity (E:T 50:1) compared
to non‑selenocompound pre‑treatment (44±9%). However,
pre‑treatment with SeMet could not induce any significant
additional cytotoxicity (46±8%, P>0.05). Furthermore,
MamA2.1 activated CD8+ T cells did not induce any cytotoxicity on HLA‑A2+/MamA‑ MCF‑7 (Fig. 3D) and MDA‑MB‑231
(Fig. 3E) breast cancer cell lines, thus suggesting that the
MamA2.1 activated CD8+ T cells exerted cytotoxic effector
functionality on breast cancer cells in Mam‑A antigen‑specific
manner. Taken together, these data demonstrated that MSA
and DMDSe induced HLA class I expression leading enhanced
antigen presentation of immunodominant antigenic peptides
following potential anti‑cancer vaccination leading to breast
cancer cell elimination.
Increased IFNγ signaling in CD8+ T cells following activa‑
tion by methylselenol producing selenocompound pre‑treated
THP‑1 cells. As interferon (IFN)‑γ signaling plays a critical role
in cytotoxic CD8+ T lymphocyte responses, we determined the
expression of IFN signaling molecules. Using methodologies
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Figure 2. Expression of components involved in the APM of breast cancer cell lines following treatment with selenocompounds. (A) Western blot analysis and
(B) mRNA levels of the APM components in THP‑1 cells following treatment with SeMet (50 µM), MSA (2.5 µM) or DMDSe (2.5 µM). Data are presented
as the mean ± SEM (n=4). Statistical significance was determined using a Tukey HSD test compared with non‑treatment conditions. *P<0.05 vs. 0 µM . APM,
antigen presentation machinery; SeMet, selenomethionine; MSA, methylselenic acid; DMDSe, methylselenol derivative dimethyl selenol; Rel, relative; TAP,
transporter associated with antigen processing; β2M, β2‑microglobulin.

Figure 3. Cytotoxic potential of CTLs following activation by MamA2.1 peptide and co‑stimulation with selenocompounds pre‑treated THP‑1 cells.
(A) Experimental design schematic. Cytotoxicity of CTLs following activation by MamA2.1 peptide and THP‑1 cells pre‑treated with SeMet (50 µM), MSA
(2.5 µM) or DMDSe (2.5 µM) in (B) AU565 (HLA‑A2+/Mam‑A+), (C) UACC‑812 (HLA‑A2+/Mam‑A+), (D) MCF‑7 (HLA‑A2+/Mam‑A‑) and (E) MDA‑MB‑231
(HLA‑A2+/Mam‑A‑) cells. E:T ratios of 50:1, 25:1, 12.5:1 and 6.25:1 are presented. Data are presented as the mean ± SEM (n=4). Statistical significance was
determined via one‑way ANOVA. *P<0.05 vs. 0 µM. CTLs, CD8+ T lymphocytes; SeMet, selenomethionine; MSA, methylselenic acid; DMDSe, methylselenol
derivative dimethyl selenol; HLA, human leukocyte antigen; E:T, effector:target.

described above, we determined the transcript levels of IFN
signaling molecules in MamA2.1 activated CD8+ T cells at

4 h following co‑culture with AU565 cells at E:T ratio of 50:1.
As shown in Fig. 4A, CD8+ T cell activation by THP‑1 cells
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Figure 4. Upregulation of IFNγ signaling in CTLs following activation by the MamA2.1 peptide and co‑stimulation with selenocompound pre‑treated THP‑1
cells. (A) Expression of components involved in the IFNγ signaling pathway molecules in CD8+ T cells following activation with MamA2.1 peptide, and in
THP‑1 cells pre‑treated with SeMet (10 µM), MSA (2.5 µM) or DMDSe (2.5 µM). (B) Quantity of IFNγ protein secreted in the supernatant following the
4 h incubation of MamA2.1 activated CTLs and AU565 cells at an E:T ratio of 50:1, as determined via ELISA. (C) Cytotoxicity of CTLs on AU565 at an E:T
ratio 50:1 upon blocking of IFNγ and HLA‑A2 by specific monoclonal antibodies. (D) Schematic of the mechanism of action of MSA and DMDSe towards
CTL activation. Data are presented as the mean ± SEM (n=4). Statistical significance between groups were assessed using Tukey HSD pair‑wise comparisons
(A) and one‑way ANOVA for multiple comparisons (B and C) *P<0.05 vs. 0 µM. IFNγ, interferon‑γ; CTLs, CD8+ T lymphocytes; SeMet, selenomethionine;
MSA, methylselenic acid; DMDSe, methylselenol derivative dimethyl selenol; HLA, human leukocyte antigen; Rel, relative; E:T, effector:target.

pre‑treated with MSA and DMDSe induced higher expression
of IFN signaling molecules namely, Jak1, Jak2, Stat1, Stat2,
Stat3, Irf‑1, Irf‑5, Irf‑7 and Irf‑9. As these data demonstrated
there is increased transcript levels of IFN signaling molecules,
we next determined the secretory IFNγ protein concentration
in the supernatant obtained from the co‑cultures by ELISA. As
shown in Fig. 4B, ELISA based analysis of the IFNγ protein
expression in the supernatant collected from the CD8+ T cells
activated under MSA (1179±127 Pg/ml, P<0.05) and DMDSe
(983±148 pg/ml, P<0.05) pre‑treatment conditions resulted
in enhanced IFNγ expression compared to no selenocompound pre‑treatment (511±73 pg/ml). However, CD8+ T cells
activated by SeMet pre‑treatment conditions (549±91 pg/ml,
P>0.05) did not induce significant change in IFNγ expression. Furthermore, we determine the direct effector role of
the expressed IFNγ on cytotoxic functionality by performing
blocking studies. As shown in Fig. 4C, blocking with IFNγ
monoclonal antibodies (mAb) and HLA‑A2 mAb significantly inhibited the cytotoxicity of MamA2.1 activated CD8+
T lymphocytes, thus suggesting that the cytotoxic effector role
CD8+ T cells is dependent upon selenocompound mediated
upregulation of IFNγ signaling. Taken together, our current
data demonstrated that MSA and DMDSe induced HLA class
I expression and presentation of HLA‑A2 restricted antigenic
epitope for specific peptide vaccine‑like activation of CD8+
T cell leading to enhanced breast cancer cell cytotoxicity.

Discussion
Peptide and DNA based cancer vaccines have many advantages, including‑being inexpensive, convenient acquisition of
clinical‑grade peptides, easy administration, higher specificity, potency due to their stronger compatibility with targeted
proteins, and greater safety with few side effects (20,21).
Previous studies from our laboratory have demonstrated safety
and immune efficiency of mammaglobin‑A, breast cancer
specific tumor associated antigen, based DNA vaccine in breast
cancer patients (16,22). The efficiency of these vaccination
strategies have limited success as cancer cells downregulate
surface expression of HLA class I molecules causing loss of
identification of tumor cells by the host CTLs (23).
While the exact mechanism by which the trace element
selenium (Se) exerts anti‑cancer potential is unknown, our
current study demonstrates that MSA and DMDSe, synthetic
selenocompound and precursor of methylselenol, induced
MHC class I surface expression on professional antigen
presenting‑like THP‑1 cells. This data is in line with studies
from other laboratories which have demonstrated enhanced
HLA class I expression by these compounds in other cancer
cell lines such as melanoma cells. In contrast, the SeMet based
selenocompounds which do not produce methylselenol failed
to induce HLA class I surface expression. This hypothesis is
in accordance to results by Hagemann‑Jensen et al, where in,
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they have shown that MSA and DMDSe mediated upregulation of NKG2D receptor ligands (19).
The antigenic peptides loaded on HLA class I molecules
and identified by CD8+ T lymphocytes generally originate from
the degradation of intracellular proteins by proteasomes and
translocation to the lumen of the endoplasmic reticulum (ER)
by the transporter associated with antigen processing (TAP)1/2
heterodimeric complex. Defects in this antigen‑processing
machinery and, in particular, in TAP subunits, have been
described as a major mechanism used by several tumors to escape
from CTL attack (24). Evidence for antitumor CTL was provided
by isolation of tumor‑specific CTL from peripheral blood or
tumor tissue of patients with diverse cancers, such as melanoma
and lung carcinoma (25). The IFNγ mediated pro‑inflammatory
mileu is critical for the priming and effector responses by CTLs
following antigen presentation by HLA class I molecules (26). The
CTLs can lyse target cells via the perforin granule exocytosis by
the IFNγ mediated JAK/STAT pathway. In our current study we
demonstrated that the induction of HLA‑A2 by MSA and DMDSe
was associated with transcriptional upregulation of components
of the APM, including proteasomal subunits and components of
the peptide loading complex, along with upregulation of IFNγ
signaling, such as the upregulation of JAK/STAT/IRF molecules.
Our current study is limited to testing HLA class I expression in mononuclear tumor‑infiltrating antigen presenting
macrophage‑like cells. However, the exact efficiency of selenocompounds towards HLA expression on cancer cells could not
be tested in our current in vitro system. In an in vitro system
cancer cell lines already had enhanced cell surface expression
of HLA class I molecules. To directly test this effect of selenocompounds on cancer cells, would require in vivo based studies
in murine or other small animal tumor models. Further we have
currently utilized peptide‑based model to study adjuvant effect
of selenocompounds, however, future studies with Mam‑A
DNA‑vaccine based model should be utilized to study the
adjuvant effect of selenocompounds on DNA‑based anti‑cancer
vaccines. Future studies utilizing in vivo model will provided a
stronger evidence for human clinical application.
In conclusion, our data provides a new adjuvant approach
to further potentiate anti‑cancer vaccine strategies. Further, we
have demonstrated that MSA and DMDSe could upregulate
the MHC class I expression in cancer cells which would enable
anti‑cancer vaccine induced activated CTLs to inhibit tumor
immune‑evasion and promote cancer immune‑elimination.
Therefore, we think novel anti‑cancer strategies utilizing inclusion of MSA and DMDSe will improve vaccine therapeutic
outcomes by enhancing CTL mediated immune‑surveillance
and cancer cell elimination.
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